ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, ArriVent expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of common stock and shares of common stock underlying pre-funded warrants on the same terms and conditions. All of the securities are being offered by ArriVent.